Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic MelanomaDavid B. Solit, Paul B. Chapman, Daniel G. Coit et al.|Clinical Cancer Research|2008Cited by 188
Supplementary Data from Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic MelanomaDavid B. Solit, Paul B. Chapman, Iman Osman et al.|Unknown|2023Cited by 0
Data from Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic MelanomaDavid B. Solit, Paul B. Chapman, Iman Osman et al.|Unknown|2023Cited by 0
Data from Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic MelanomaDavid B. Solit, Paul B. Chapman, Iman Osman et al.|Unknown|2023Cited by 0
Supplementary Data from Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic MelanomaDavid B. Solit, Paul B. Chapman, Iman Osman et al.|Unknown|2023Cited by 0